Silverback Therapeutics, Inc. - Common Stock (NQ:SBTX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Nov 8, 2022 Add to My Watchlist

Price and Volume

Volume	0
Open	-
Bid (Size)	2.500 (1)
Ask (Size)	6.150 (3)
Prev. Close	5.870
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	95,568,307
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

February 23, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

February 22, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

More News

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

February 09, 2023

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

Once A Cancer Company, Silverback Merges With Small Biotech Working On Allergy Treatment ↗

July 22, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

May 11, 2022

Via Benzinga

Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce ↗

April 01, 2022

Via Benzinga

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

November 10, 2022

From ARS Pharmaceuticals, Inc.

Via GlobeNewswire

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

November 08, 2022

From Silverback Therapeutics, Inc.

Via GlobeNewswire

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

October 21, 2022

From Silverback Therapeutics, Inc.

Via Business Wire

SILVERBACK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Silverback Therapeutics, Inc. - SBTX

October 14, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silverback Therapeutics, Inc. (Nasdaq - SBTX), One Medical (Nasdaq - ONEM), Hanger, Inc. (NYSE - HNGR), VMware, Inc. (NYSE - VMW)

July 26, 2022

From Brodsky & Smith LLC

Via GlobeNewswire

SILVERBACK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Silverback Therapeutics, Inc. - SBTX

July 22, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday ↗

July 25, 2022

Via Benzinga

Daily Biotech Pulse: VistaGen's Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal's Lead Asset ↗

July 22, 2022

Via Benzinga

This Consumer Defensive Stock Is Trading Higher By Around 49%, Here Are 46 Stocks Moving In Friday's Mid-Day Session ↗

July 22, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

July 22, 2022

Via InvestorPlace

Why Guardforce AI is Trading Higher By 36%: Here's 24 Stocks Moving Premarket ↗

July 22, 2022

Via Benzinga

SBTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Silverback Therapeutics, Inc. Is Fair to Shareholders

July 21, 2022

From Halper Sadeh LLP

Via Business Wire

Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

July 21, 2022

From Silverback Therapeutics, Inc.

Via Business Wire

Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

May 17, 2022

From Silverback Therapeutics, Inc.

Via Business Wire

Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 12, 2022

From Silverback Therapeutics, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022 ↗

April 04, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

April 01, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 1, 2022 ↗

April 01, 2022

Via Benzinga

Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

March 31, 2022

From Silverback Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Silverback Therapeutics, Inc. - Common Stock publicly traded?

Yes, Silverback Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Silverback Therapeutics, Inc. - Common Stock trade on?

Silverback Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Silverback Therapeutics, Inc. - Common Stock?

The ticker symbol for Silverback Therapeutics, Inc. - Common Stock is SBTX on the Nasdaq Stock Market